A Study to Assess an ATX Inhibitor (IOA-289) in Healthy Volunteers
Randomized, Double-blind, Placebo-controlled, Dose Escalation Study for the Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of IOA-289 in Healthy Male Volunteers
Sponsor: iOnctura
This PHASE1 trial investigates Healthy and is currently completed. iOnctura leads this study, which shows 9 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Apr 2025 — Present [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Jan 2025 — Apr 2025 [monthly]
Recruiting PHASE1
-
Dec 2024 — Jan 2025 [monthly]
Recruiting PHASE1
-
Oct 2024 — Dec 2024 [monthly]
Recruiting PHASE1
Status: Completed → Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Completed PHASE1
▶ Show 4 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Feb 2022 — Nov 2022 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Sep 2021 — Feb 2022 [monthly]
Recruiting PHASE1
First recorded
Jun 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- iOnctura
For direct contact, visit the study record on ClinicalTrials.gov .